Under construction – not a live service
Sign in
Taking people in FranceNo phase

Tests an early warning score to guide ICU admission in blood cancer patients

Tests an early warning score for ICU transfer in adults with blood cancers.

Plain-language title generated from the registry record
Registry title: Impact of an Early Warning System on the Prognosis of Patients With Hematological Malignancies Receiving Intensive Chemotherapy With or Without Hematopoietic Cell Transplantation.

Key facts

Where
Amiens, Angers, Besançon, Brest, Nancy, Nantes, Poitiers, Saint-Etienne, Strasbourg, and Tours, FranceSee the 10 sites

Where in France

  • Centre Hospitalier Amiens-PicardieAmiens, FranceTaking people
  • Centre Hospitalier Universitaire D'AngersAngers, FranceTaking people
  • Centre Hospitalier Universitaire -BesançonBesançon, FranceTaking people
  • Centre Hospitalier Universitaire BrestBrest, FranceTaking people
  • Centre Hospitalier universitaire NancyNancy, FranceTaking people
  • Centre Hospitalier Universitaire NantesNantes, FranceTaking people
  • Centre Hospitalier Universitaire poitiersPoitiers, FranceTaking people
  • centre Hospitalier Universitaire Saint etienneSaint-Etienne, FranceTaking people
  • centre Hospitalier Universitaire StrasbourgStrasbourg, FranceNot yet recruiting
  • centre Hospitalier Universitaire ToursTours, FranceTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
University Hospital, Angers
Trial code
NCT06409767
Record updated
24 September 2025
Original description
Patients with hematologic malignancies requiring intensive chemotherapy are at risk for life-threatening complications. Organ failure may appear rapidly and delay in initiating life-sustaining interventions may result in increased mortality. This encourages great alertness although not all patients require close monitoring. It is therefore critical to identify which patients are the most at risk for clinical deterioration to consider increased surveillance in these patients. The benefit of early intensive care unit (ICU) admission, as soon as the first signs of organ dysfunction appear, must also be clarified. Such an intervention could increase survival of patients by close monitoring and early initiation of organ-specific interventions but could also be responsible for anxiety and increased use of ICU resources.Read full original descriptionShow less

Impact of an Early Warning System on the Prognosis of Patients With Hematological Malignancies Receiving Intensive Chemotherapy With or Without Hematopoietic Cell Transplantation, a Multicenter Cluster Randomized Study

Patients with hematologic malignancies requiring intensive chemotherapy are at risk for life-threatening complications. Organ failure may appear rapidly and delay in initiating life-sustaining interventions may result in increased mortality. This encourages great alertness although not all patients require close monitoring. It is therefore critical to identify which patients are the most at risk for clinical deterioration to consider increased surveillance in these patients. The benefit of early intensive care unit (ICU) admission, as soon as the first signs of organ dysfunction appear, must also be clarified. Such an intervention could increase survival of patients by close monitoring and early initiation of organ-specific interventions but could also be responsible for anxiety and increased use of ICU resources.

Many teams have analyzed the impact of early warning systems (EWS) including vital signs to detect organ dysfunction early on. It has been shown that these EWS could positively impact survival in many medical fields (pre-hospital, medicine or surgery departments). A few retrospective studies have explored the impact of EWS in hematology, with overall good prediction for ICU admission and mortality. Until now, it has however not been formally demonstrated that early ICU admission, as soon as the first signs of organ dysfunction appear, could benefit patients with hematologic malignancies. A randomized controlled trial studying the impact of early intervention would clarify the role of such a strategy.

In this study, the investigators will prospectively evaluate the implementation of the National Early Warning Score (NEWS), with systematic referral to the ICU in high-score patients, to improve the survival of patients receiving intensive chemotherapy in ten academic centers. This score is one of the most performant and most frequently used to predict organ failure. Its calculation only requires vital signs such as respiratory rate, peripheral oxygen saturation, need for oxygen therapy, body temperature, arterial pressure, heart rate, and level of consciousness. The investigators will therefore study the impact of ICU admission in patients with high NEWS in a randomized, controlled trial. A cluster randomization is planned in which the centers will be randomized between usual care (control group) and interventional care with transfer to the ICU in the event of a NEWS score ≥7 (interventional group). Each parameter used to calculate the NEWS will be collected at least three times a day by the attending nurse.

Inclusion: Adult patient; Hospitalization in a protected unit of a hematology department for induction therapy of acute myeloid leukemia or acute lymphoblastic leukemia induction, intensive chemotherapy with autologous hematopoietic cell transplantation, allogeneic hematopoietic cell transplantation; Expected length of stay in the hematology department of at least 7 days; Patient with social security; Signed informed consent form.

Exclusion: Hospitalization for Chimeric Antigenic Receptor (CAR) T-cell therapy; Person under forced psychiatric care; Decision of care limitation with decision not to transfer to ICU or not initiate organ support; Pregnant, parturient or breastfeeding woman; Person deprived of liberty by judicial or administrative decision; Person under legal protection; Person unable to express consent.

ClinicalTrials.gov NCT06409767